DataMeds AI's Oncology Lab and GLP-1 App Deals: Reading a Trading-Desk Report

On October 12, 2026, StocksToTrade reported that shares of DataMeds AI Inc. (Nasdaq: MEDS) were trading up 13.34% after the company announced partnerships in AI-based clinical diagnostics ^[1]. The trading-news site linked the move to a run of recent announcements: a completed acquisition of the cancer diagnostics lab Helomics, a GLP-1 telehealth app launched with Tollo Health, and preliminary September revenue at the company's Corexa Pharmacy division ^[1]. The piece is market commentary aimed at active traders, so it reports deal terms and price moves rather than clinical evidence ^[1].

What the report describes

• Helomics. DataMeds AI closed a $1.5M acquisition of Helomics, which the story calls an AI-driven cancer diagnostics lab and a precision oncology CRO (contract research organisation) ^[1]. According to the story, DataMeds took on the lab, its equipment and its contracts, received $1.5M in cash, and avoided third-party legacy debt ^[1].
• Health Lives Here. This mobile app, launched with Tollo Health, targets the GLP-1 weight-loss and diabetes market ^[1]. It combines telehealth, pharmacy, nutrition, wearables and behavioural health in one product ^[1].
• Corexa Pharmacy. The division reported preliminary, unaudited September 2026 revenue above $1M, more than 66% higher than in July ^[1].
• Wellgistics settlement. Settling litigation tied to a 2023 deal erased roughly $19M in liabilities and retired 364,099 shares in exchange for a $450,000 cash payment ^[1].

Why it matters for care teams

The story describes the app as fitting with the Corexa and Helomics assets, and later as tying telehealth and pharmacy together ^[1]. It does not say who prescribes through the app, what clinical protocols it follows, how patient information reaches a patient's existing clinicians, or what outcomes it has produced ^[1]. For clinicians whose patients mention the app, this source offers no clinical detail ^[1].

The Helomics deal places a cancer diagnostics laboratory inside the same company as a pharmacy and a consumer app ^[1]. The story describes the lab as CLIA/CAP-certified, but that description comes from trading commentary, and the report points to no regulatory or accreditation record behind it ^[1]. It also calls the lab AI-driven without saying which tests it runs or how its AI methods have been evaluated ^[1].

The report also sets out the company's finances ^[1]. It puts trailing revenue at about $23.3M ^[1]. For the quarter ending June 30, 2026, it reports about $1.78M in revenue, more than $9.1M in expenses and a net loss above $18.3M ^[1]. It also describes negative equity, heavy current liabilities and cash of about $2.46M ^[1]. The site calls MEDS a "story stock", pointing to fast revenue growth on one side and serious cash burn and dilution risk on the other ^[1].

The story reports large share-price moves around two earlier announcements, the Helomics closing and the app launch ^[1]. It says the stock rose more than 300% after the Helomics deal closed, with other reports putting the surge at about 305% ^[1]. It also reports gains of roughly 20% to 39% around the app launch ^[1]. The article expects the price to keep moving on news catalysts rather than on conventional value measures ^[1].

What to watch next

• Whether the September Corexa revenue figure holds up in audited reporting, since the story labels it preliminary and unaudited ^[1].
• The company's upcoming telehealth summit presentation and its AI-focused rebrand, both of which the story mentions without detail ^[1].
• Any published information on which tests the Helomics lab runs and how its AI tools are evaluated, which this report does not provide ^[1].
• Follow-through on the app, since the story warns that a failed follow-through or a disappointing update could reverse sentiment quickly ^[1].